All In Biotech

Free tool

FAERS Monitor: Tepezza

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761143 or its brand name (Tepezza, Teprotumumab-Trbw). Reports on generic versions are filed under their own applications.

Reports

5,951

Serious

2,588

43% of reports

Hospitalization

505

Death reported

41

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • muscle spasms1,156
  • fatigue822
  • tinnitus627
  • hypoacusis504
  • headache499
  • diarrhoea462
  • blood glucose increased458
  • nausea453
  • alopecia441
  • endocrine ophthalmopathy375
  • pain360
  • anxiety350
  • diplopia329
  • weight decreased321
  • drug ineffective301

Reports by year received

View as table
YearReports
2020475
2021692
2022727
2023732
20241,869
2025702
2026754

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,208 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
endocrine ophthalmopathySignal3752690.42358.0571,088
tinnitusSignal62748.945.429,032
diplopiaSignal32945.340.814,052
hypoacusisSignal50441.938.519,863
muscle spasmsSignal1,15622.421.323,668
blood glucose increasedSignal4588.67.93,093
alopeciaSignal4418.07.32,693
anxietySignal3504.43.9911
weight decreasedSignal3214.13.7749
fatigueSignal8223.73.51,704
headacheSignal4992.82.6599
diarrhoeaSignal4622.52.3439
painSignal3602.11.9204
nauseaSignal4532.01.9242
drug ineffective3010.80.715

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.